Literature DB >> 6172389

Reversibility of the transformed and neoplastic phenotype. I. Progressive reversion of the phenotype of X-ray-transformed C3H/10T1/2 cells under prolonged treatment with interferon.

D Brouty-Boyé, I Gresser.   

Abstract

X-ray transformed mouse C3H/10T1/2 cells were cultivated and passaged in the continuous presence of partially purified mouse interferon. This prolonged interferon treatment resulted in a stepwise progressive reversion of the transformed phenotype to the non-transformed phenotype. Thus interferon-treated cells displayed an epithelioid morphology, grew to a lower cell density, and were no longer tumorigenic. Reversion to the non-transformed phenotype was, however, stable only as long as interferon was continuously present in the culture medium. When interferon was removed, the cells "back reverted" to the transformed phenotype. Our results suggest that interferon induced a reversion of the transformed phenotype in the entire cell population rather than a selection of an interferon resistant cell population. C-type viral particles and significant levels of reverse transcriptase were present in transformed cells, but neither present in the parental 10T1/2 cells nor in interferon-treated cells. When interferon was removed form the culture medium, viral particles and reverse transcriptase activity were again detected. It is possible, therefore, that interferon induces reversion through its antiviral activity, or that it induces reversion by its effects on cell function and structure, independently of any antiviral effect. Inhibition of cell multiplication per se does no appear to be sufficient to induce reversion, since cycloheximide inhibited cell multiplication; however, even after ten passages, it did not affect tumorigenicity. Our results suggest the possibility that interferon may act in vivo not only by inhibiting tumor cell multiplication but also by inducing a reversion. Patients with some tumors may therefore benefit from long-term interferon treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6172389     DOI: 10.1002/ijc.2910280209

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  The significance of biological heterogeneity.

Authors:  H Rubin
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

Review 2.  Interferon and reversion of the transformed phenotype.

Authors:  D Brouty-Boyé
Journal:  Surv Immunol Res       Date:  1982

3.  Reversibility of the transformed and neoplastic phenotype. III. Long-term treatment with electrophoretically pure mouse interferon leads to the progressive reversion of the phenotype of X-ray transformed C3H/10T1/2 cells.

Authors:  D Brouty-Boyé; F Puvion-Dutilleul; I Gresser
Journal:  Experientia       Date:  1982-11-15

4.  Interferons as antitumor agents.

Authors:  H Kirchner
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

5.  Persistent expression of v-mos oncogene in transformed cells that revert to nonmalignancy after prolonged treatment with interferon.

Authors:  D Sergiescu; J Gerfaux; A M Joret; C Chany
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 6.  The interferons.

Authors:  J L Toy
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

Review 7.  The antitumor effects of interferon.

Authors:  I Gresser
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

8.  Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice.

Authors:  P Ramani; F R Balkwill
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

9.  Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice.

Authors:  I Gresser; C Carnaud; C Maury; A Sala; P Eid; D Woodrow; M T Maunoury; F Belardelli
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.